AAV Potentiator Polypeptides: Unlocking Deeper Tissue Penetration for Next-Generation Gene Therapy
This technology comprises a novel class of "potentiator polypeptides", proteins co-administered with adeno-associated viruses (AAVs), that dramatically enhance viral tissue penetration, spread and infectivity by precisely and temporarily reducing the structural and molecular barriers that normally trap AAVs near the injection site. By enabling AAVs to reach deeper tissue targets more efficiently, this platform has the potential to significantly lower therapeutic doses, broaden treatable indications, and improve outcomes across a wide range of gene therapy applications.
Description
Adeno-associated viruses are the leading vector for in vivo gene therapy, yet their clinical utility is limited by a fundamental biological obstacle: unwanted interactions with physical and molecular barriers that sequester viral particles near the injection site before they can reach intended target cells. In the retina, for example, intravitreally injected AAV is largely retained at the Inner Limiting Membrane (ILM), with only a small fraction penetrating to photoreceptors. This necessitates higher doses, raising safety and manufacturing cost concerns. The technology addresses this limitation through the co-administration of potentiator polypeptides alongside AAV vectors. These polypeptides precisely and temporarily modify the tissue environment around the injection site, allowing AAVs to bypass structural barriers and penetrate deeper into the target tissue. The technology is compatible with multiple AAV serotypes and all of their engineered variants, can be formulated as a combined composition or as a two-component co-injection system, and because it acts on the tissue environment rather than on the vector itself, it functions as a simple additive to any AAV.Applications
- Ocular gene therapy: Intravitreal or subretinal delivery for retinal degenerative diseases including macular degeneration, retinitis pigmentosa, Leber congenital amaurosis, choroideremia, and other inherited retinal disorders.- CNS gene therapy: Improved AAV penetration for neurological disease targets in the brain where structural barriers limit vector spread.
- Hepatic gene therapy: Enhanced liver delivery for metabolic and genetic disorders such as hemophilia, Fabry disease, and lysosomal storage diseases.
- Cardiac gene therapy: Improved myocardial transduction for heart failure or inherited cardiomyopathies.
- Oncology: AAV-mediated therapeutic gene delivery to solid tumors, where tissue density limits vector distribution.
Advantages
- Enhanced tissue penetrance and spread: Potentiator polypeptides enable AAVs to bypass structural barriers and reach deep target cell populations, such as photoreceptors from intravitreal injections, that are otherwise poorly accessible- Dose reduction potential: By improving delivery efficiency, equivalent or superior therapeutic effect may be achievable at lower viral doses, reducing manufacturing cost and safety burden
- Broad platform applicability: Compatible with any AAV serotype and engineered variants, enabling wide use across gene therapy programs. AAV potentiators act on the tissue environment rather than on the vector itself, functioning as a simple additive that can be used ad-hoc with any existing AAV and therapeutic payload, without requiring any modification to the vector.
- Flexible formulation: Can be delivered as a single combined composition or as separate co-administered components, providing formulation versatility
- Clinically relevant protein candidates: All disclosed potentiators are naturally occurring or derived from human proteins, potentially supporting favorable safety and immunogenicity profiles.